BMEA Biomea Fusion, Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:30
Jan 24
Jan 24
Bullish BMEA on T2D data and 2026 Phase 2b catalysts
Author is heavily long Biomea Fusion because December 2025 icovamenib T2D data showed durable C-peptide/insulin-secretion improvements suggesting beta-cell functional restoration and disease modification, setting up Phase 2b execution. Catalysts include COVALENT-211/212 first-patient enrollment in Q1 2026, 28-day BMF-650 obesity Phase 1 results in Q2 2026, and both Phase 2b 26-week readouts in Q4 2026 that could re-rate the small-cap. Stated risks include Phase 2b execution/endpoints, FDA alignment, brutal GLP-1 competition, and financing/dilution.
HIGH
19:47
Jan 15
Jan 15
JPM presentation de-risked BMEA; expect gradual probability re-rating
Author argues Biomea Fusion’s JPM CEO presentation materially de-risked BMEA by framing icovamenib as disease-modifying in insulin-deficient T2D and GLP-1-refractory patients rather than transient early data. The company’s tight, purpose-built Phase 2b and regulatory-anchored language reduce perceived execution and FDA risk, with execution expected in 2025–2026. The author expects the market to gradually re-rate the probability of success over days to weeks and remains constructive/long.
HIGH
About BMEA Investor Commentary
Across the available history and selected sources, Buzzberg tracks BMEA (Biomea Fusion, Inc. Common Stock) across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/United-Collar-944.